Fig. 5.

Effect of cisplatin treatment on apoptosis-regulatory proteins. a, b HFDPC and HaCaT cells were treated with cisplatin (0–250 and 0–50 µM in HFDPC and HaCaT cells, respectively) in the presence or absence of NAC (2.5 mM) for 24 h. Cell lysates were prepared and analyzed for Bcl-2, Bax, and pro-caspase 3 (Pro-C3) expression by western blotting. Blots were reprobed with β-actin antibody to confirm equal loading of samples. Immunoblot signals were quantified by densitometry, and mean data from three independent experiments (one of which is shown here) was normalized to the result obtained in cells without treatment (control). c, d HFDPC and HaCaT cells were similarly treated with cisplatin in the presence or absence of NAC for 15 h, and analyzed for caspase-3 activity using the fluorometric substrate FAM-DEVD-fmk. e, f HFDPC and HaCaT cells were treated with cisplatin (100 and 25 µM in HFDPC and HaCaT cells, respectively) for various times (0–24 h), and Bcl-2 and Bax expression was determined. Plots are mean ± SD (n = 3). *P < 0.05 versus non-treated control. ^#P < 0.05 versus cisplatin-treated control